Table 1 Risk management for an Unaffected Female BRCA1/2 Mutation Carrier
Cancer type | Recommendation | |
|---|---|---|
Breast | Surgical | ▪ offer bilateral risk-reducing mastectomy followed by self-surveillance of breast area. The greatest benefit is predicted when surgery occurs at age ≤40 years |
▪ alternatively in the absence of bilateral risk-reducing mastectomy, recommend RRSO preferably around age 40 years | ||
Surveillance | ▪ in families with breast cancer diagnosed under age 35 years, individualised screening recommendations may apply | |
▪ otherwise screening should start at age 30 years | ||
▪ 30–50 years – annual MRI + MMG (+/− US) | ||
▪ >50 years – annual MMG +/− US | ||
▪ pregnant - no MRI or MMG, consider US | ||
Risk-reducing medication | ▪ careful assessment of risks and benefits in the individual case by an experienced medical professional is required when considering the use of medication, such as tamoxifen or raloxifene to reduce risk of developing breast cancer in unaffected women. See Cancer Australia Risk-reducing medication resource | |
Ovarian/fallopian tube | Surgical | ▪ recommend RRBSO after family completion or around age 40 years3 with peritoneal lavage and close histological examination to exclude occult malignancy |
Surveillance | ▪ do not offer serum CA125 and/or transvaginal ultrasound (TVU) | |
Pancreatic | ▪ no evidence of benefit from surveillance | |